藥明(ming)康(kang)德(de)8月21日(ri)晚(wan)披露(lu)半(ban)年(nian)(nian)報,公(gong)司2018年(nian)(nian)上半(ban)年(nian)(nian)實現營(ying)收44.09億元,同(tong)(tong)比增(zeng)長(chang)(chang)20.29%,歸屬于上市公(gong)司股(gu)(gu)東的凈利潤為12.72億元,同(tong)(tong)比增(zeng)長(chang)(chang)71.31%。基本每股(gu)(gu)收益(yi)1.31元。
半年(nian)報(bao)(bao)顯示,報(bao)(bao)告期內,公(gong)司(si)實(shi)現(xian)(xian)主營業務(wu)收入(ru)44.03億(yi)元(yuan),較(jiao)2017年(nian)同期增(zeng)長20.88%。得益于現(xian)(xian)有(you)客戶(hu)的業務(wu)量持續增(zeng)加以及(ji)新(xin)(xin)增(zeng)客戶(hu)的不(bu)斷拓展,公(gong)司(si)各(ge)板塊業務(wu)新(xin)(xin)增(zeng)客戶(hu)800余(yu)家。中國區(qu)實(shi)驗(yan)室(shi)服務(wu)實(shi)現(xian)(xian)收入(ru)24.17億(yi)元(yuan),同比(bi)增(zeng)長21.65%;美國區(qu)實(shi)驗(yan)室(shi)服務(wu)實(shi)現(xian)(xian)收入(ru)5.46億(yi)元(yuan),同比(bi)下降1.93%;臨(lin)床研究及(ji)其他CRO服務(wu)實(shi)現(xian)(xian)收入(ru)2.31億(yi)元(yuan),同比(bi)增(zeng)長58.80%;CMO/CDMO業務(wu)實(shi)現(xian)(xian)收入(ru)12.09億(yi)元(yuan),同比(bi)增(zeng)長26.80%。(張(zhang)興旺)